Bristol-Myers Squibb Co. said Friday the drug Opdivo was approved by European regulators as skin cancer treatment.
The drug is already approved the U.S. as a treatment for skin and lung cancer.
Continue Reading Below
The approval allows for the sale of the drug in the 28 countries that belong to the European Union.
Opdivo had $40 million in worldwide revenue during the first quarter of 2015.